Login to Your Account



NewCo News

New 'Genesis' for Viragen's Anti-CD55 Cancer Program

By Jennifer Boggs


Friday, December 17, 2010
Failed biotech Viragen Inc. might have called it quits in 2007, but its monoclonal antibody targeting CD55 was reborn in start-up Genesis Biopharma Inc., which licensed the CD55-related assets earlier this year and plans to move forward with testing in both solid tumors and blood cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription